Daclizumab
Daclizumab
CLINICAL USE
Humanised murine/human monoclonal anti-CD25 antibody:Prophylaxis of acute allograft rejection, in combination with maintenance immunosuppressants
DOSE IN NORMAL RENAL FUNCTION
1 mg/kg within 24 hours of transplantation, then 1 mg/kg every 14 days for 5 doses. See ‘Other Information’
PHARMACOKINETICS
Molecular weight                           :144 000 %Protein binding                           :No data %Excreted unchanged in urine     : No data Volume of distribution (L/kg)       :5.3 litreshalf-life – normal/ESRD (hrs)      :270–919/– DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Dose as in normal renal function HD                     :Not dialysed. Dose as in normal renal functionHDF/high flux   :Unknown dialysability. Dose as in normal renal functionCAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsNone known ADMINISTRATION
Reconstition
– Route
IV infusion
Rate of Administration
Over 15 minutes Comments
Add required dose to 50 mL of sodium chloride 0.9%Stable for 24 hours at 2–8°C if prepared aseptically OTHER INFORMATION
An alternative dosing regimen that may be used is 2 mg/kg every 14 days for 2 doses
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home